ATE411013T1 - Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom - Google Patents

Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom

Info

Publication number
ATE411013T1
ATE411013T1 AT02770441T AT02770441T ATE411013T1 AT E411013 T1 ATE411013 T1 AT E411013T1 AT 02770441 T AT02770441 T AT 02770441T AT 02770441 T AT02770441 T AT 02770441T AT E411013 T1 ATE411013 T1 AT E411013T1
Authority
AT
Austria
Prior art keywords
adults
receptor antagonist
glucocorticoid receptor
down syndrome
cognitive performance
Prior art date
Application number
AT02770441T
Other languages
English (en)
Inventor
Joseph Belanoff
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Application granted granted Critical
Publication of ATE411013T1 publication Critical patent/ATE411013T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Casting Support Devices, Ladles, And Melt Control Thereby (AREA)
  • Toilet Supplies (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02770441T 2001-08-31 2002-08-27 Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom ATE411013T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31665301P 2001-08-31 2001-08-31

Publications (1)

Publication Number Publication Date
ATE411013T1 true ATE411013T1 (de) 2008-10-15

Family

ID=23230024

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02770441T ATE411013T1 (de) 2001-08-31 2002-08-27 Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom

Country Status (15)

Country Link
US (1) US7402578B2 (de)
EP (1) EP1432379B1 (de)
JP (2) JP2005501882A (de)
KR (1) KR20040029116A (de)
CN (2) CN1556708A (de)
AT (1) ATE411013T1 (de)
CA (1) CA2459033C (de)
DE (1) DE60229411D1 (de)
ES (1) ES2314103T3 (de)
IL (1) IL160649A0 (de)
MX (1) MXPA04001893A (de)
NO (1) NO332723B1 (de)
NZ (1) NZ531477A (de)
WO (1) WO2003020216A1 (de)
ZA (1) ZA200401754B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1652526E (pt) * 2001-10-26 2009-02-06 Organon Nv Utilização de (11β,17β)-11-(1,3-benzodioxol-5-il)-17-hidroxi-17-(1-propinil)-estra-4,9-dien-3-ona no tratamento de desordem depressiva grave
WO2008093227A1 (en) 2007-02-02 2008-08-07 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
CA2728563C (en) * 2008-07-01 2017-05-30 Corcept Therapeutics, Inc. Use of mifepristone for the treatment of amyotrophic lateral sclerosis
PL2576582T3 (pl) * 2010-05-26 2020-06-29 Corcept Therapeutics, Inc. Leczenie dystrofii mięśniowej
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US9457141B2 (en) 2013-06-03 2016-10-04 Bigfoot Biomedical, Inc. Infusion pump system and method
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
AU2019404026B2 (en) 2018-12-19 2023-06-08 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
KR20230017829A (ko) 2020-05-27 2023-02-06 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제 렐라코릴란트 및 cyp2c8과 cyp3a4의 이중 기질인 파클리탁셀의 병용 투여
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
US12433882B2 (en) 2022-10-28 2025-10-07 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0969830A1 (de) * 1997-02-05 2000-01-12 Allelix Pharm-Eco L.P. Verbindungen zur verbesserung des gedächtnisses
CN1187053C (zh) * 1997-10-06 2005-02-02 利兰·斯坦福青年大学托管委员会 糖皮质素受体拮抗剂用于制造治疗精神病药物的用途
IL139672A (en) * 1998-05-15 2005-11-20 Univ Leland Stanford Junior Glucocorticoid receptor antagonists for the tretment of dementia
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
WO2002017930A2 (en) * 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
JP2004537563A (ja) * 2001-07-23 2004-12-16 コーセプト セラピューティクス， インコーポレイテッド 抗神経病薬誘導性体重増加を予防するための方法

Also Published As

Publication number Publication date
CA2459033A1 (en) 2003-03-13
NO332723B1 (no) 2012-12-27
JP2009102343A (ja) 2009-05-14
IL160649A0 (en) 2004-07-25
ZA200401754B (en) 2005-05-25
DE60229411D1 (de) 2008-11-27
NZ531477A (en) 2006-10-27
CA2459033C (en) 2012-05-22
JP2005501882A (ja) 2005-01-20
EP1432379A1 (de) 2004-06-30
HK1062533A1 (en) 2004-11-12
WO2003020216A1 (en) 2003-03-13
US7402578B2 (en) 2008-07-22
NO20041338L (no) 2004-05-28
ES2314103T3 (es) 2009-03-16
CN1868480A (zh) 2006-11-29
EP1432379A4 (de) 2005-07-13
CN1556708A (zh) 2004-12-22
NO20041338D0 (no) 2004-03-31
MXPA04001893A (es) 2005-03-07
US20030064974A1 (en) 2003-04-03
KR20040029116A (ko) 2004-04-03
EP1432379B1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
ATE406166T1 (de) Verfahren zur prävention von gewichtszunahme infolge von antipsychotika
ATE317699T1 (de) Glucocorticoid receptor antagonisten zur behandlung von demenz
DE60229411D1 (de) Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom
WO2002076390A3 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
NO20003534D0 (no) Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
DE69835225D1 (de) Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
ATE498395T1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
HK1047050A1 (zh) 治疗轻度智力机能缺陷的方法
WO2004069202A3 (en) Antiglucocorticoids for the treatment of postpartum psychosis
EP0928419A4 (de) Zusammensetzungen und verfahren zur regulierung der expression des type-i-interleukin-1-rezeptors
DE60238671D1 (de) Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium
NO20042500L (no) Chemokin-reseptorantagonister og metoder for anvendelse derav
IL149357A0 (en) Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
AU2002219192A1 (en) Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
TR199800488T1 (xx) Diskinezi i�in 5-HT3 resept�r antagonistleri.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties